Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts

Faizal Z. Asumda, Nellie A. Campbell, Mohamed A. Hassan, Reza Fathi, Daniella F. Vasquez Rico, Melanie Kiem, Ethan V. Vang, Yo Han Kim, Xin Luo, Daniel R. O’Brien, Sarah A. Buhrow, Joel M. Reid, Michael J. Moore, Vered Katz Ben-Yair, Mark L. Levitt, Jennifer L. Leiting, Amro M. Abdelrahman, Xinli Zhu, Fabrice Lucien, Mark J. TrutyLewis R. Roberts

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts'. Together they form a unique fingerprint.

Medicine & Life Sciences